Mylan said on Wednesday its fourth-quarter earnings fell due to declining revenue from its EpiPen emergency allergy injector and weak U.S. prices for generic drugs.
The drugmaker reported net income of $ 244.3 million, or 46 cents a share, in the quarter, down from $ 417.5 million, or 78 cents a share, last year.
Excluding one-time items, the company said it earned $ 1.43 a share. Analysts on average were expecting $ 1.41, according to Thomson Reuters.
Revenue in the quarter fell 1 percent to $ 3.24 billion, coming in below the average analyst expectation of $ 3.3 billion.
Mylan forecast adjusted earnings per share in the range of $ 5.20 to $ 5.60 for 2018, in line with analyst estimates.